Mr. Damien McCallion:

On cancer drugs, the spend has gone up to €650 million from €240 million in 2017. That is just one context and it is across all areas. It is estimated because it is quite complex to calculate across our hospitals, but it relates to our primary care reimbursement scheme, our hospitals and other areas. We have a robust approval process for new drugs. There have been challenges. As the Senator said, there was a report done by Mazars that we are implementing. We are putting more resources in place to try to ensure that what is needed will be available. That has been an advance on one level.

In terms of early access to drugs, which is another requirement and pressure, we are in a process, which I will get into today, with the Department, the pharmaceutical association and the Government to try to look at how that might develop.

That is work in progress, so I am not going to get into it. Clearly, those negotiations are at a sensitive point. We are trying to approve and shorten the cycle for the normal process around drug approvals. We are satisfied that the process it goes through is fairly robust but we are conscious of the timeline. I will hand over to Mr. Canavan.